Which is a good argument against medication that just lowers GDF15 levels. But if you approach it as "what lifestyle changes lower GDF15" then there's a good chance that those changes would also attack the actual reason for dementia.
But how often does the medication development process check the result we care about: "does this medication then go on to reduce the chance of dementia?"